Trial Profile
A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jul 2021
Price :
$35
*
At a glance
- Drugs Daridorexant (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Idorsia Pharmaceuticals
- 11 Jun 2021 Results published in the Sleep
- 09 Jun 2021 According to an Idorsia Pharmaceuticals media release, data from this study will be presented at the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society conducted virtually from June 10-13 (SLEEP 2021).
- 18 Dec 2019 Status changed from recruiting to completed.